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Background: Motor impairment in Parkinson’s disease (PD) can be evaluated with the Short Parkinson’s
Evaluation Scale/Scales for Outcomes in Parkinson’s disease (SPES/SCOPA) and the Movement Disorder
Society-Uniﬁed Parkinson’s Disease Rating Scale (MDS-UPDRS). The aim of this study was to determine
equation models for the conversion of scores from one scale to the other.
Methods: 148 PD patients were evaluated with the SPES/SCOPA-motor and the MDS-UPDRS motor
examination. Linear regression was used to develop equation models.
Results: Scores on both scales were highly correlated (r ¼ 0.88). Linear regression revealed the following
equation models (explained variance: 78%):
1. MDS-UPDRS motor examination score ¼ 11.8 þ 2.4 * SPES/SCOPA-motor score
2. SPES/SCOPA-motor score ¼ 0.5 þ 0.3 * MDS-UPDRS motor examination score.
Conclusion: With the equation models identiﬁed in this study, scores from SPES/SCOPA-motor can be
converted to scores from MDS-UPDRS motor examination and vice versa. 2011 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Although the clinical spectrum of Parkinson’s disease (PD) has
broadened to include non-motor features, motor features are still
the most frequently evaluated features. They deﬁne the cardinal
set of disease characteristics, are in part responsive to dopami-
nergic interventions, and have proved reliable characteristics
to measure disease progression. Over time, numerous rating
scales have been introduced to evaluate PD motor features [1].
The growing recognition of clinimetric deﬁcits of existing rating
scales fuelled developments to improve these instruments. For
example, because of consorted efforts of the Movement Disorder
Society, the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS) [2]
has evolved into an instrument with better clinimetric proper-
ties, the MDS-UPDRS [3,4]. However, an important limitation of
the MDS-UPDRS is its duration. Mean completion time for the, K5Q-92, Leiden University
he Netherlands. Tel.: þ31 71
sevier OA license.investigator part is 30 min, including 15 min for the motor
examination part only [4], which may be problematic in clinical
and research settings. The duration along with the clinimetric
weaknesses of the earlier version of the scale (UPDRS) created
the need for a brief, valid and reliable rating scale for the eval-
uation of PD [5]. First, the Short Parkinson’s Evaluation Scale
(SPES) was developed, which is a simple and short scale for the
assessment of motor impairment and disabilities in PD [6]. Later,
the SCales for Outcomes in PArkinson’s disease (SCOPA) study
proposed several modiﬁcations to the SPES in order to improve
the clinimetric aspects of the scale, which resulted in a new PD
rating scale, the SPES/SCOPA [7]. Like the MDS-UPDRS, the
SPES/SCOPA is reliable and valid [7,8], but has a much shorter
total administration time of 8.1 min [7]. This advantage makes
the SPES/SCOPA-motor a good alternative to the MDS-UPDRS
motor examination for settings with limited time or staff to
assess patients.
Since the SPES/SCOPA-motor and MDS-UPDRS motor examina-
tion differ in the number, content and scaling of items, scores of the
two scales cannot easily be compared. The aim of this study was to
determine equation models for the conversion of scores from one
scale to the other.
D. Verbaan et al. / Parkinsonism and Related Disorders 17 (2011) 632e634 6332. Methods
2.1. Participants
All patients fulﬁlled the United Kingdom Parkinson’s Disease
Society Brain Bank criteria for idiopathic PD [9]. Patients visiting the
outpatient clinic of the Leiden University Medical Center (LUMC)
were included, whereas some patients were recruited from general
practices in the vicinity. There were no exclusion criteria. Most
patients were assessed at the LUMC. To avoid bias towards
recruiting less severely affected patients, patients whowere unable
to come to the hospital were assessed at home. This study was
approved by the medical ethical committee of the LUMC and all
patients gave written informed consent.2.2. Assessment procedure
Patients were evaluated with the SPES/SCOPA-motor [7], the
MDS-UPDRS motor examination [4] and the Hoehn and Yahr scale
(H&Y) [10]. The SPES/SCOPA-motor includes 14 items (Table 1) with
four response options, ranging from 0 (normal) to 3 (severe) (range
0e42). The MDS-UPDRS motor examination includes 33 items
(Table 1) with ﬁve response options, ranging from 0 (normal) to 4
(severe) (range 0e132). All patients were examined by the same
investigator trained in assessing the included scales. Age, sex, age at
onset (ﬁrst symptoms as perceived by the patient), disease dura-
tion, medication, and patients’ state during the assessment (“on” or
“off”), were also recorded. For each patient a levodopa dosage
equivalent (LDE) was calculated [11].2.3. Statistical analysis
If data from the SPES/SCOPA-motor or MDS-UPDRS motor exa-
mination was missing (for both scales this had to be less than 25%),
the mean score of the non-missing items of that scale of that patient
was imputed to replace the missing value(s). The Kolmogor-
oveSmirnov test was performed to test if the distributions of the
SPES/SCOPA-motor or MDS-UPDRS motor examination scores
showed deviations from normality. The relation between the MDS-Table 1
Items of the SPES/SCOPA-motor and the MDS-UPDRS motor examination.
SPES/SCOPA-motor MDS-UPDRS motor examination
1. Rest tremor; LUE, RUE 1. Rest tremor; lip/jaw, LUE, RUE, LLE, RLE
2. Constancy of rest tremor
2. Postural tremor; LUE, RUE 3. Postural tremor; LUE, RUE
4. Kinetic tremor; LUE, RUE
3. Rapid alternating movements
of hands; LUE, RUE
5. Finger tapping; LUE, RUE
6. Hand movements; LUE, RUE
7. Pronationesupination movements
of hands; LUE, RUE
8. Toe tapping; LLE, RLE
9. Leg agility; LLE, RLE
4. Rigidity; LUE, RUE 10. Rigidity; neck, LUE, RUE, LLE, RLE
5. Rise from chair 11. Arising from chair
6. Postural instability 12. Postural instability
7. Gait 13. Gait
8. Speech 14. Speech
9. Swallowing
15. Facial expression
10. Freezing during “on” 16. Freezing of gait
17. Posture
18. Global spontaneity of movement
(body bradykinesia)
LUE: left upper extremity; RUE: right upper extremity; LLE: left lower extremity;
RLE: right lower extremity.UPDRS motor examination and the SPES/SCOPA-motor scores was
assessed with Pearson’s correlation coefﬁcient. Spearman’s rho was
used to assess the relation between both scores and disease severity
(H&Y). Correlation coefﬁcients were deﬁned as very weak
(r¼ 0e0.19), weak (r¼ 0.20e0.39), moderate (r¼ 0.40e0.59), strong
(r ¼ 0.60e0.79) and very strong (r ¼ 0.80e1.00) [12]. Simple linear
regression models were used to construct equation models for the
conversion of scores from one scale to the other. Multiple forward
linear regression analysis was used to explore if any remaining
unexplained variance could be attributed to other variables (age,
gender, disease duration, H&Y score, and LDE). A p-value < 0.05 was
considered signiﬁcant. All analyses were performed with SPSS 16.0.3. Results
A total of 148 PD patients (67% men) with a mean (SD) age of
66.9 (9.6) years participated. Patients’ mean (SD) age of onset was
55.2 (12.0) and their mean disease duration was 11.6 (6.6) years.
Most patients had a mild or moderate disease severity (H&Y stage:
1 (1%), 2 (59%), 3 (18%), 4 (16%), and 5 (6%)). 83% of the patients used
levodopa and 54% of the patients used dopamine-agonists. The
mean (SD) total LDE was 720.1 (569.4) mg/day. Most patients (91%)
were “on” during the assessment, whereas some were “off” (4%) or
did not use any antiparkinsonian medication (5%).
Overall, 51 items (1.0% of the total MDS-UPDRS items in this
study) and 4 items (0.2% of the total SPES/SCOPA items in this
study) were missing and imputed for the MDS-UPDRS and the
SPES/SCOPA-motor, respectively. The mean (SD) motor scores were
14.9 (5.8) (SPES/SCOPA-motor, range 3e32), and 48.0 (16.0) (MDS-
UPDRS motor examination, range 17e88). Both motor scores were
very strongly related (r ¼ 0.88, p < 0.001). The distributions of the
scores of the SPES/SCOPA-motor and the MDS-UPDRS motor
examination showed no major deviations from normality (Kolmo-
goroveSmirnov: p ¼ 0.390 and p ¼ 0.554, respectively). Correla-
tions betweenmotor scores and disease severity (H&Y) were strong
to moderate (SPES/SCOPA-motor: rs ¼ 0.64, p < 0.001, MDS-UPDRS
motor examination: rs ¼ 0.57, p < 0.001).
The equation model for the conversion of SPES/SCOPA-motor
scores into MDS-UPDRS motor examination scores was: MDS-
UPDRS motor examination score ¼ 11.8 þ 2.4 * SPES/SCOPA-motorFig. 1. Scatterplot with regression line (95% CI) and explained variance of the relation
between SPES/SCOPA-motor scores and MDS-UPDRS motor examination scores.
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(Fig. 1). Additional to the 78% explained variance by the SPES/
SCOPA-motor score, LDE and age both explained 1% of the remai-
ning variance of the MDS-UPDRS motor examination score (total
model, p < 0.001).
The equation model for the conversion of MDS-UPDRS motor
examination scores into SPES/SCOPA-motor scores was: SPES/
SCOPA-motor score ¼ 0.5 þ 0.3 * MDS-UPDRS motor examina-
tion score (p < 0.001). Additional to the 78% explained variance by
the MDS-UPDRS motor examination score, H&Y (3%), and LDE (1%)
explained 4% of the remaining variance of the SPES/SCOPA-motor
score (total model, p < 0.001).
4. Discussion
In clinical research, standardized rating scales are of tremen-
dous value for the reliable evaluation of participants. The MDS-
UPDRS motor examination and the SPES/SCOPA-motor are rating
scales for the evaluation of motor impairments in PD with good
clinimetric properties [4,7]. Although both scales in essence
capture the same information, the MDS-UPDRS motor examination
requires signiﬁcantly more time. Arguments to choose one or the
other may depend on the setting, time, and staff available.
Regardless of which instrument is used, it remains desirable that
results of different studies can be compared. To permit comparisons
between studies using the SPES/SCOPA-motor and those using the
MDS-UPDRS motor examination, equation models were developed
to allow conversion of scores from one scale to the other.
The MDS-UPDRS was only recently launched. Therefore, this is
the ﬁrst study evaluating the relation between the SPES/SCOPA-
motor and the MDS-UPDRS motor examination. Correlations
between the SPES/SCOPA-motor and the earlier UPDRS motor
examination have been calculated previously and showed similar
or higher (r ¼ 0.88 and r ¼ 0.96) coefﬁcients when compared to the
correlation coefﬁcient found in this study [7,8].
The maximum explained variance of a model in which scores
from one instrument are converted to the other, will partly depend
on the measurement errors of both instruments and will therefore
never be 100%. However, in order to consider a conversionmodel as
reliable, the explained variance should be high, and the additional
explained variance of other inﬂuencing variables should be
minimal. In our study, both assumptions were met with an
explained variance of 78% and a minimal additional explained
variance of other variables (2% and 4%).
Although the conversion models can be considered reliable,
differences between scales regarding number, content and scaling
of items may have inﬂuenced the percentage of explained variance.
Firstly, some items are only included in one of the scales (Table 1).
Secondly, although both scales assess the most important PDmotor
aspects, the MDS-UPDRS motor examination addresses resting
tremor, bradykinesia, and rigidity more comprehensively. Thirdly,
for some symptoms differences exist between scales in content or
execution. For instance, postural instability is tested with (MDS-
UPDRS) or without (SPES/SCOPA) a preceding warning. Fourthly,
the scales differ in the number of response options; four (SPES/
SCOPA) and ﬁve (MDS-UPDRS), respectively. Finally, although the
evaluation of patients in this study was as accurate and thorough aspossible, there were some missing values. Imputation of missing
values may add noise to the actual results, and therefore imputa-
tion of missing values in this study may have led to some loss of
variance, although this effect is negligible in our study since the
number of missing values was very low.
Although patients in this study reﬂected a wide range of age,
disease severity, disease duration and age of onset, the study
sample had a relatively young mean age at onset and a high
percentage of patients in H&Y stage 2, compared to the general PD
population. A higher percentage of patients in H&Y stages 1 and 5
would probably have had some inﬂuence on the equation models,
but it is difﬁcult to predict the amount as well as the direction of
change within the models. Conclusively, SPES/SCOPA-motor scores
can easily be converted to MDS-UPDRS motor examination scores
and vice versa, using the equation models calculated in this study,
which makes comparisons between studies using the different
scales possible. Additionally, it presents an alternative for situations
in which time or staff constraints limit the use of the lengthier
MDS-UPDRS.Acknowledgements
This work was supported by grants from the Prinses Beatrix
Fonds (PBF, project no. WAR05-0120), the van Alkemade-Keuls
Foundation and the Dutch Parkinson’s Disease Society.References
[1] Ramaker C, Marinus J, Stiggelbout AM, van Hilten BJ. Systematic evaluation of
rating scales for impairment and disability in Parkinson’s disease. Mov Disord
2002;17:867e76.
[2] Fahn S, Elton RL, members of the UPDRS Development Committee. Uniﬁed
Parkinson’s disease rating scale. Florham Park, NJ: Macmillan Healthcare
Information; 1987.
[3] Movement Disorder Society Task Force on Rating Scales for Parkinson’s
Disease. The Uniﬁed Parkinson’s Disease Rating Scale (UPDRS): status and
recommendations Mov Disord 2003;18:738e50
[4] Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al.
Movement Disorder Society-sponsored revision of the Uniﬁed Parkinson’s
Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing
results. Mov Disord 2008;23:2129e70.
[5] Van Hilten JJ, Van Der Zwan AD, Zwinderman AH, Roos RA. Rating impairment
and disability in Parkinson’s disease: evaluation of the Uniﬁed Parkinson’s
Disease Rating Scale. Mov Disord 1994;9:84e8.
[6] Rabey JM, Bass H, Bonuccelli U, Brooks D, Klotz P, Korczyn AD, et al. Evaluation
of the Short Parkinson’s Evaluation Scale: a new friendly scale for the evalu-
ation of Parkinson’s disease in clinical drug trials. Clin Neuropharmacol 1997;
20:322e37.
[7] Marinus J, Visser M, Stiggelbout AM, Rabey JM, Martinez-Martin P,
Bonuccelli U, et al. A short scale for the assessment of motor impairments and
disabilities in Parkinson’s disease: the SPES/SCOPA. J Neurol Neurosurg
Psychiatry 2004;75:388e95.
[8] Martinez-Martin P, Benito-Leon J, Burguera JA, Castro A, Linazasoro G, Mar-
tinez-Castrillo JC, et al. The SCOPA-Motor Scale for assessment of Parkinson’s
disease is a consistent and valid measure. J Clin Epidemiol 2005;58:674e9.
[9] Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of
idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988;51:
745e52.
[10] Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality.
Neurology 1967;17:427e42.
[11] Esselink RA, de Bie RM, de Haan RJ, Lenders MW, Nijssen PC, Staal MJ, et al.
Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD:
a randomized trial. Neurology 2004;62:201e7.
[12] Swinscow TDV, Campbell MJ. Statistics at square one. London: BMJ Books;
2002.
